Rocuronium B. Braun
Rocuronium bromide – Neuromuscular Blocking Agent for General Anesthesia
Rocuronium B. Braun is a non-depolarizing neuromuscular blocking agent used during general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery. Administered only by anesthesiologists in hospital settings, rocuronium bromide works by blocking nerve impulses at the neuromuscular junction. This comprehensive guide covers indications, dosage, side effects, drug interactions, and storage requirements.
Quick Facts
Key Takeaways
- Rocuronium is a non-depolarizing neuromuscular blocking agent that provides muscle relaxation during surgery and facilitates endotracheal intubation for mechanical ventilation.
- It has a rapid onset of action (60–90 seconds at standard doses) with an intermediate duration of approximately 30–40 minutes, making it one of the most widely used muscle relaxants in modern anesthesia.
- The effects can be rapidly and completely reversed with sugammadex (Bridion), a selective reversal agent, even from deep neuromuscular blockade.
- Rocuronium must only be administered by experienced anesthesiologists or clinicians trained in airway management, with facilities for mechanical ventilation immediately available.
- Patients with neuromuscular disorders (e.g., myasthenia gravis), hepatic impairment, or electrolyte imbalances may require significant dose adjustments and enhanced monitoring.
What Is Rocuronium B. Braun and What Is It Used For?
Quick Answer: Rocuronium B. Braun is a neuromuscular blocking agent (muscle relaxant) used during general anesthesia to relax skeletal muscles, making it easier for surgeons to operate and for anesthesiologists to place a breathing tube (endotracheal intubation).
Rocuronium bromide belongs to a class of medications known as non-depolarizing neuromuscular blocking agents (NMBAs). These drugs work by competitively binding to nicotinic acetylcholine receptors at the neuromuscular junction—the point where nerve cells communicate with muscle cells. Under normal circumstances, the neurotransmitter acetylcholine is released from motor neurons, crosses the neuromuscular junction, and binds to receptors on the muscle fiber, triggering a contraction. Rocuronium blocks this process by occupying those receptor sites, preventing acetylcholine from exerting its effect and thereby producing reversible skeletal muscle paralysis.
In clinical practice, rocuronium is one of the most frequently used neuromuscular blocking agents worldwide. It was first approved for clinical use in the 1990s and has since become a mainstay of modern anesthesia due to its favorable pharmacological profile. Unlike succinylcholine, which is a depolarizing agent, rocuronium does not cause fasciculations (involuntary muscle twitching) before inducing paralysis and is not associated with hyperkalemia, malignant hyperthermia, or masseter muscle rigidity in susceptible individuals.
The primary indications for rocuronium include:
- Facilitation of endotracheal intubation: During general anesthesia in both adults and children, rocuronium relaxes the muscles of the jaw, vocal cords, and upper airway, allowing smooth placement of a breathing tube for mechanical ventilation.
- Muscle relaxation during surgery: Surgical procedures requiring a still, relaxed operative field—such as abdominal, thoracic, or orthopedic surgeries—benefit from the deep muscle relaxation provided by rocuronium.
- Rapid sequence intubation (RSI): At higher doses (0.9–1.2 mg/kg), rocuronium can be used for emergency intubation in adults when rapid airway control is needed, providing adequate intubating conditions within 45–60 seconds.
- Intensive care unit (ICU) use: In adult patients requiring short-term facilitation of mechanical ventilation, rocuronium may be used as an adjunct in the ICU, although prolonged use carries risks of critical illness myopathy.
Rocuronium is particularly valued in modern anesthesia because its neuromuscular blockade can be specifically and rapidly reversed by sugammadex (Bridion), a modified gamma-cyclodextrin molecule. Sugammadex encapsulates rocuronium molecules in the plasma, forming an inactive complex that is excreted renally. This reversal mechanism is unique among neuromuscular blocking agents and has significantly improved patient safety by allowing anesthesiologists to reverse even deep neuromuscular blockade within minutes.
What Should You Know Before Receiving Rocuronium B. Braun?
Quick Answer: Rocuronium should not be used in patients with known hypersensitivity to rocuronium bromide. Special caution is required in patients with neuromuscular disorders, liver disease, kidney disease, electrolyte imbalances, or cardiovascular conditions.
Contraindications
Rocuronium B. Braun must not be administered to patients who have a known allergy (hypersensitivity) to rocuronium bromide or to any of the excipients in the formulation. Cross-sensitivity between neuromuscular blocking agents has been documented; therefore, patients who have experienced an anaphylactic reaction to any other neuromuscular blocking agent should be considered at increased risk when receiving rocuronium. In such cases, the anesthesiologist will conduct a thorough risk-benefit assessment and may perform skin testing before administration.
Warnings and Precautions
Your anesthesiologist should be informed of the following conditions before rocuronium is administered, as they may affect the drug's action or increase the risk of complications:
- Allergy to neuromuscular blocking agents: Previous allergic or anaphylactic reactions to any neuromuscular blocking agent increase the risk of cross-reactivity.
- Kidney, liver, or biliary tract disease: Rocuronium is primarily metabolized and eliminated via hepatic uptake and biliary excretion. Hepatic or biliary disease can significantly prolong the duration of action, requiring reduced doses and careful monitoring.
- Cardiovascular disease: Conditions affecting circulation may alter the onset and distribution of the drug.
- Edema (fluid retention): Increased volume of distribution may affect drug concentrations and onset time.
- Neuromuscular disorders: Conditions such as myasthenia gravis, Eaton-Lambert syndrome, or poliomyelitis dramatically increase sensitivity to rocuronium. Significantly reduced doses may be required, and prolonged blockade is common.
- Hypothermia during anesthesia: Low body temperature reduces the metabolism and clearance of neuromuscular blocking agents, prolonging their effects.
- Electrolyte imbalances: Hypocalcemia (low calcium), hypokalemia (low potassium), hypermagnesemia (high magnesium), and acidosis can potentiate the neuromuscular blocking effects of rocuronium.
- Burns patients: Resistance to non-depolarizing neuromuscular blocking agents may develop in patients with burns, potentially requiring higher doses.
- Obesity: Dose adjustments based on ideal body weight rather than actual body weight may be necessary in obese patients to avoid prolonged blockade.
- Elderly patients: The elderly may experience a prolonged duration of action due to age-related decreases in hepatic and renal function.
Rocuronium must only be administered by or under the close supervision of an experienced anesthesiologist who is familiar with the use, actions, and complications of neuromuscular blocking agents. Facilities for endotracheal intubation, mechanical ventilation, and cardiopulmonary resuscitation must be immediately available. Neuromuscular monitoring equipment should be used to guide dosing and to confirm recovery from neuromuscular blockade before extubation.
Pregnancy and Breastfeeding
Clinical data on the use of rocuronium during pregnancy are limited. Animal reproduction studies have not demonstrated evidence of teratogenicity; however, the potential risks to the human fetus have not been fully established. Rocuronium should only be administered during pregnancy when the treating physician determines that the expected benefits clearly outweigh the potential risks to the fetus. It is approved for use during cesarean section delivery.
There are no data available regarding the excretion of rocuronium in human breast milk. Given the clinical setting of its use (hospital-based anesthesia), the exposure to nursing infants is expected to be minimal. However, the decision to administer rocuronium to a breastfeeding mother should weigh the benefits of treatment against any potential risk to the infant. No data are available regarding the effects of rocuronium on human fertility.
Driving and Operating Machinery
Rocuronium has a significant effect on the ability to drive and use machinery. As it is administered as part of general anesthesia, patients should not drive or operate potentially dangerous machinery for at least 24 hours after full recovery from the drug's effects. Patients should be accompanied home by a responsible adult after the procedure. The treating physician will advise when it is safe to resume normal activities.
How Does Rocuronium B. Braun Interact with Other Drugs?
Quick Answer: Many medications can enhance or reduce the effects of rocuronium, including volatile anesthetics, antibiotics, cardiac medications, and anticonvulsants. Your anesthesiologist will review all your current medications before administering rocuronium.
Drug interactions with rocuronium are clinically significant because they can either potentiate (increase) or antagonize (reduce) the degree and duration of neuromuscular blockade. The anesthesiologist will take all concurrent medications into consideration when calculating the appropriate dose. Below is a comprehensive overview of known interactions.
Drugs That Enhance Neuromuscular Blockade
The following medications may increase the intensity or prolong the duration of rocuronium's effects, potentially requiring dose reductions:
| Drug/Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Volatile anesthetics (sevoflurane, isoflurane, desflurane) | Enhance neuromuscular blockade via central and peripheral mechanisms | High – dose reduction of 30–40% typically required |
| Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) | Reduce acetylcholine release at neuromuscular junction | High – may cause recurarization post-reversal |
| Magnesium salts | Reduce acetylcholine release, decrease motor end-plate sensitivity | High – profound potentiation of blockade |
| Calcium channel blockers (verapamil, nifedipine) | Interfere with calcium-dependent neuromuscular transmission | Moderate – may prolong recovery |
| Lithium | Alters neuromuscular transmission | Moderate – unpredictable prolongation |
| Quinidine | Reduces muscle fiber excitability | Moderate – may cause recurarization |
| Loop diuretics (furosemide) | Hypokalemia enhances neuromuscular blockade | Moderate – correct electrolyte levels |
| Corticosteroids (prolonged ICU use) | Combined with NMBAs, increases risk of critical illness myopathy | High – may cause prolonged weakness |
Drugs That Reduce Neuromuscular Blockade
The following medications may reduce the efficacy of rocuronium, potentially requiring higher doses:
- Phenytoin and carbamazepine: Chronic use of these anticonvulsants accelerates the hepatic metabolism and clearance of rocuronium, resulting in resistance to neuromuscular blockade and potentially requiring 50–80% higher doses.
- Theophylline: May antagonize neuromuscular blockade through phosphodiesterase inhibition.
- Protease inhibitors: Some antiviral agents may reduce the effects of neuromuscular blocking agents.
- Neostigmine, pyridostigmine, and edrofonium: Cholinesterase inhibitors used to treat myasthenia gravis will antagonize the effects of rocuronium, though this same mechanism is used therapeutically for reversal of neuromuscular blockade at the end of surgery.
Sugammadex is a modified gamma-cyclodextrin specifically designed to encapsulate rocuronium (and to a lesser extent vecuronium) molecules. It provides rapid, dose-dependent reversal of neuromuscular blockade, even from deep block. Sugammadex reverses rocuronium through a completely different mechanism than traditional cholinesterase inhibitors, offering more predictable and complete reversal with fewer side effects. It is now considered the preferred reversal agent for rocuronium-induced blockade in many countries.
What Is the Correct Dosage of Rocuronium B. Braun?
Quick Answer: The standard adult intubating dose is 0.6 mg/kg body weight, producing adequate intubating conditions within 60–90 seconds with a duration of 30–40 minutes. Dose adjustments are required based on the clinical setting, patient age, concurrent medications, and individual response.
Rocuronium is administered intravenously (IV) either as a bolus injection or as a continuous infusion. The dose is individualized based on the patient's body weight, age, clinical condition, concurrent medications, and the type of anesthesia being used. Neuromuscular monitoring with a peripheral nerve stimulator (e.g., train-of-four monitoring) is recommended to guide dosing and ensure adequate recovery before extubation.
Adults
Standard Intubation
Dose: 0.6 mg/kg IV bolus
Onset: 60–90 seconds
Duration: 30–40 minutes
This dose provides excellent to good intubating conditions in most patients within 60 seconds.
Rapid Sequence Intubation (RSI)
Dose: 0.9–1.2 mg/kg IV bolus
Onset: 45–60 seconds
Duration: 50–70 minutes
Used in emergency situations where rapid airway control is critical. Higher doses provide a faster onset but significantly longer duration.
Maintenance Doses
Bolus: 0.1–0.2 mg/kg as needed
Infusion: 0.3–0.6 mg/kg/hour (5–10 mcg/kg/min)
Maintenance doses are guided by neuromuscular monitoring. When using volatile anesthetics, the infusion rate should be reduced by 30–40%.
Children and Adolescents
Rocuronium can be administered to neonates (0–27 days), infants (28 days to 23 months), children (2–11 years), and adolescents (12–17 years). The standard intubating dose is the same as for adults (0.6 mg/kg), though the pharmacokinetics differ across pediatric age groups.
| Age Group | Intubation Dose | Onset | Duration | Special Considerations |
|---|---|---|---|---|
| Neonates (0–27 days) | 0.6 mg/kg | ~60 seconds | Variable | Increased sensitivity; prolonged duration; careful titration required |
| Infants (28 days–23 months) | 0.6 mg/kg | ~60 seconds | ~30 min | May require higher maintenance infusion rates |
| Children (2–11 years) | 0.6 mg/kg | ~60 seconds | ~25–30 min | Shorter duration; higher infusion rates often needed |
| Adolescents (12–17 years) | 0.6 mg/kg | ~60 seconds | ~30–40 min | Similar to adult pharmacokinetics |
Experience with rocuronium for rapid sequence intubation in children and adolescents is limited; therefore, it is not routinely recommended for this indication in the pediatric population.
Elderly Patients
Elderly patients (over 65 years) may experience a prolonged duration of action due to age-related reductions in hepatic blood flow and organ function. While the onset time is generally similar to younger adults, recovery from neuromuscular blockade may be significantly delayed. The anesthesiologist will typically use standard intubating doses but will monitor more closely and may extend the intervals between maintenance doses. Careful neuromuscular monitoring is particularly important in this population.
Hepatic and Renal Impairment
Patients with hepatic or biliary tract disease may show a delayed onset and, more notably, a significantly prolonged duration of action because rocuronium is primarily cleared via hepatic uptake and biliary excretion. Dose reductions and extended monitoring are recommended. In patients with renal impairment, the pharmacokinetics of rocuronium are generally not significantly altered at standard doses, though caution is advised in severe renal failure.
Overdose
In the event of an overdose, the patient may experience prolonged and profound muscle paralysis. The anesthesiologist will maintain mechanical ventilation and sedation until neuromuscular function recovers spontaneously or is pharmacologically reversed. Sugammadex is the preferred reversal agent in cases of rocuronium overdose, as it can rapidly reverse even deep neuromuscular blockade. Alternatively, neostigmine with an anticholinergic agent can be used for reversal of moderate blockade. Neuromuscular monitoring is essential to confirm complete recovery before discontinuing ventilatory support.
What Are the Side Effects of Rocuronium B. Braun?
Quick Answer: The most commonly reported side effects include injection site pain, increased heart rate (especially in children), and changes in blood pressure. Serious but rare side effects include anaphylactic reactions, bronchospasm, and prolonged neuromuscular blockade.
Like all medicines, rocuronium can cause side effects, although not everyone experiences them. The following side effects have been reported in clinical trials and post-marketing surveillance. Your anesthesiologist will monitor you closely during and after administration to detect and manage any adverse reactions promptly.
Tell your healthcare provider immediately if you experience signs of a severe allergic reaction: skin rash, itching, breathing difficulties, low blood pressure, rapid heart rate, facial or throat swelling, or hives. Anaphylactic reactions to rocuronium are rare but can be life-threatening and require immediate treatment with epinephrine and supportive care.
Uncommon/Rare
May affect up to 1 in 100 to 1 in 1,000 patients
- Tachycardia (increased heart rate)*
- Hypotension (low blood pressure)
- Injection site pain or reactions
- Prolonged neuromuscular blockade (delayed recovery)
- Inadequate or altered drug response
- Delayed recovery from anesthesia
Very Rare
May affect up to 1 in 10,000 patients
- Anaphylactic/anaphylactoid reactions (severe allergic reactions including shock)
- Bronchospasm (wheezing, airway constriction)
- Elevated histamine levels
- Paralysis (immobility)
- Muscle weakness (myopathy – especially after prolonged ICU use with corticosteroids)
Frequency Not Known
Reported in post-marketing surveillance
- Respiratory arrest
- Respiratory failure
- Kounis syndrome (allergic coronary artery spasm) – may present as chest pain or heart attack
- Mydriasis (dilated pupils) or fixed pupils unresponsive to light
*Note on tachycardia in children: Clinical studies indicate that an increased heart rate is common in pediatric patients (may affect up to 1 in 10 children), making it more frequent in this population compared to adults.
Critical Illness Myopathy
Prolonged use of rocuronium in the intensive care unit (ICU), particularly when combined with corticosteroids, has been associated with the development of critical illness myopathy—a condition characterized by prolonged, generalized muscle weakness that can persist for weeks to months after discontinuation of the drug. For this reason, the duration of neuromuscular blockade in the ICU should be kept to the minimum necessary, and patients should be regularly assessed for return of muscle function.
Anaphylaxis to Neuromuscular Blocking Agents
While very rare, anaphylactic reactions to neuromuscular blocking agents represent one of the most common causes of perioperative anaphylaxis. Rocuronium has been identified as one of the more frequently implicated agents. Patients with a history of anaphylaxis to any neuromuscular blocking agent should be thoroughly evaluated before receiving rocuronium or any other NMBA. Skin testing and specific IgE assays may help identify patients at risk. In the event of anaphylaxis, standard emergency protocols should be followed, including administration of epinephrine, IV fluids, and supportive care.
How Should You Store Rocuronium B. Braun?
Quick Answer: Store at or below 25°C (77°F). Use immediately after opening. Diluted solutions are stable for up to 24 hours at room temperature. Do not use if the solution is not clear or contains particles.
Proper storage of rocuronium is essential to maintain its potency and safety. The following guidelines apply to Rocuronium B. Braun 10 mg/ml solution for injection/infusion:
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- After opening: The product should be used immediately after the ampoule is opened. It is intended for single use only; discard any unused solution.
- After dilution: Solutions diluted to 5.0 mg/ml or 0.1 mg/ml with 0.9% sodium chloride or 5% glucose are chemically and physically stable for up to 24 hours at room temperature when exposed to daylight, in both glass and plastic containers.
- Microbiological considerations: From a microbiological perspective, the diluted product should be used immediately. If not used immediately, storage should not exceed 24 hours at 2–8°C (36–46°F), unless dilution was performed under controlled and validated aseptic conditions.
- Visual inspection: Do not use this medicine if the solution is not clear or if particles are visible.
- Expiration date: Do not use after the expiration date printed on the label and carton (EXP). The expiration date refers to the last day of that month.
- Keep out of reach of children.
Rocuronium B. Braun is compatible with 0.9% sodium chloride solution and 5% glucose solution for dilution. It is physically incompatible with many other medications, including amphotericin, dexamethasone, diazepam, furosemide, hydrocortisone sodium succinate, insulin, methylprednisolone, thiopental, and vancomycin, among others. If administered through the same IV line as other medications, the line must be thoroughly flushed with 0.9% sodium chloride between administrations.
What Does Rocuronium B. Braun Contain?
Quick Answer: Each milliliter contains 10 mg of rocuronium bromide as the active ingredient. Excipients include gluconolactone, sodium acetate trihydrate, sodium citrate, and water for injections.
Rocuronium B. Braun is a clear, colorless to slightly brownish-yellow solution for injection or infusion. The following is the complete composition:
Active Substance
- Rocuronium bromide: 10 mg per ml. Each 5 ml ampoule contains 50 mg of rocuronium bromide.
Excipients (Inactive Ingredients)
- Gluconolactone
- Sodium acetate trihydrate
- Sodium citrate
- Water for injections
Packaging
Rocuronium B. Braun is available in packages containing 20 plastic ampoules, each containing 5 ml of solution (50 mg rocuronium bromide per ampoule).
Sodium Content
This medicine contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets or those receiving multiple IV medications where cumulative sodium intake must be monitored.
Frequently Asked Questions
Rocuronium bromide is a neuromuscular blocking agent used during general anesthesia to facilitate endotracheal intubation (placement of a breathing tube) and to provide skeletal muscle relaxation during surgical procedures. It may also be used in intensive care settings to facilitate mechanical ventilation. The drug works by temporarily blocking nerve signals to muscles, causing reversible muscle paralysis that allows the surgeon to operate with an optimal, relaxed surgical field.
At the standard intubating dose of 0.6 mg/kg, rocuronium achieves adequate intubating conditions within 60 to 90 seconds. The duration of clinically effective neuromuscular blockade is approximately 30 to 40 minutes. At higher doses used for rapid sequence intubation (0.9–1.2 mg/kg), onset is faster (45–60 seconds) but duration is longer (50–70 minutes). The duration can be influenced by factors such as age, hepatic function, concurrent medications, and body temperature.
Yes, the effects of rocuronium can be reversed using two different approaches. Traditional reversal uses neostigmine combined with an anticholinergic agent (atropine or glycopyrrolate), which inhibits the enzyme that breaks down acetylcholine, allowing it to compete more effectively with rocuronium at the neuromuscular junction. The preferred modern reversal agent is sugammadex (Bridion), which directly encapsulates rocuronium molecules, providing rapid and complete reversal even from deep neuromuscular blockade, typically within 2–3 minutes.
Clinical data on rocuronium use during pregnancy are limited. It should only be administered when the physician determines that the benefits outweigh the potential risks. Rocuronium is approved for use during cesarean section deliveries. There are no data on its excretion in breast milk, but given that it is used in hospital settings during anesthesia, exposure to nursing infants is expected to be minimal. No data are available regarding effects on human fertility.
Rocuronium and succinylcholine are both neuromuscular blocking agents but work differently. Succinylcholine is a depolarizing agent with an ultra-rapid onset (30–60 seconds) and very short duration (5–10 minutes), but carries risks of hyperkalemia, malignant hyperthermia, and fasciculations. Rocuronium is a non-depolarizing agent with a slightly slower onset (60–90 seconds) and longer duration (30–40 minutes), but has a better safety profile. With the availability of sugammadex for rapid reversal, rocuronium has largely replaced succinylcholine for rapid sequence intubation in many clinical settings.
No. Because rocuronium is administered as part of general anesthesia, you should not drive or operate machinery for at least 24 hours after full recovery from its effects. You must be accompanied home by a responsible adult after the procedure. Your anesthesiologist or surgeon will advise you when it is safe to resume driving and other activities requiring alertness and coordination.
References
- European Medicines Agency (EMA). Rocuronium bromide – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Accessed January 2026.
- Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised controlled trial. European Journal of Anaesthesiology. 2010;27(10):874-881. doi:10.1097/EJA.0b013e32833d56b7
- Naguib M, Brull SJ, Kopman AF, et al. Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesthesia & Analgesia. 2018;127(1):71-80. doi:10.1213/ANE.0000000000002670
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database of Systematic Reviews. 2017;(8):CD012763. doi:10.1002/14651858.CD012763
- British National Formulary (BNF). Rocuronium bromide. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Zemuron (rocuronium bromide) Prescribing Information. Available at: www.fda.gov. Accessed January 2026.
- Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. Journal of Investigational Allergology and Clinical Immunology. 2011;21(6):442-453.
Medical Editorial Team
Medical Review
This article has been reviewed by the iMedic Medical Review Board, comprising licensed physicians specializing in anesthesiology, pharmacology, and critical care medicine. All medical claims are verified against current international guidelines and peer-reviewed literature.
Editorial Standards
iMedic follows strict editorial standards based on the GRADE evidence framework. All content undergoes multi-stage review including medical accuracy verification, readability assessment, and accessibility compliance testing. We maintain complete editorial independence with no commercial funding or pharmaceutical sponsorship.
Evidence Level: 1A – Based on systematic reviews, randomized controlled trials, and international clinical guidelines (EMA SmPC, FDA Prescribing Information, WHO Essential Medicines List, Cochrane Reviews, BNF).